Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 691 to 705 of 1094 results for infections

  1. Upadacitinib for treating active ankylosing spondylitis (TA829)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.

    Technology appraisal guidance
    Published
    30 September 2022
    View recommendations

    Sections for TA829

  2. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    2 June 2015
    View recommendations

    Sections for TA343

  3. Can rapid microbiological diagnosis of hospital-acquired pneumonia reduce the use of xtendedspectrum antibiotic therapy, without adversely affecting outcomes?

    hospital-acquired pneumonia to guide antibiotic therapy. Hospital-acquired infections can be caused by highly resistant pathogens that...

    Research recommendation
    Published
    9 June 2015

  4. TopClosure Tension Relief System for wound closure (MIB97)

    NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .

    Medtech innovation briefing
    Published
    7 March 2017

  5. Curos for preventing infections when using needleless connectors (MTG44)

    We have moved Medical technologies guidance 44 to become HealthTech guidance 510. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Neonatal parenteral nutrition (QS205)

    This quality standard covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    22 March 2022
    View quality statements

    Sections for QS205

  7. Endoscopic transluminal pancreatic necrosectomy (HTG421)

    Evidence-based recommendations on endoscopic transluminal pancreatic necrosectomy in adults. This involves removing dead tissue from the pancreas.

    HealthTech guidance
    Published
    23 November 2016
    View recommendations

    Sections for HTG421

  8. Early and late-onset meningitis: What is the optimal antibiotic treatment regimen for early-onset neonatal meningitis?

    Source guidance details Comes from guidance Neonatal infection: antibiotics for prevention and treatment Number NG195

    Research recommendation
    Published
    6 August 2021

  9. How cost effective are cohort testing programmes: - as a stand-alone programme, or - as an extension of the NHS Health Check programme?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  10. What cost-effective interventions ensure continuity of care for prisoners who are diagnosed with chronic hepatitis B or C in prison?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  11. How many children in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  12. How many people in the UK are infected with chronic hepatitis B and C and which subgroups of the population do they come from?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  13. What cost-effective interventions can be used to increase hepatitis B case-finding among migrant populations in primary and secondary care?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015

  14. Bair Hugger for measuring core temperature during perioperative care (MIB99)

    NICE has developed a medtech innovation briefing (MIB) on Bair Hugger for measuring core temperature during perioperative care .

    Medtech innovation briefing
    Published
    28 March 2017

  15. How cost effective are alternative testing sites, such as community pharmacist programmes, for increasing the number of people who are tested and treated for hepatitis B and C?

    Comes from guidance Hepatitis B and C testing: people at risk of infection Number PH43 Date issued December 2012 Other

    Research recommendation
    Published
    9 June 2015